MedEngine’s story begins in London where founders Christian Mellor and Philipp Brunnbauer were lab partners and biomedical engineers at Imperial College. After realizing the potential for a low-cost medical device that could continuously monitor Parkinson’s Disease, Mellor and Brunnbauer teamed up to found MedEngine GmbH in 2017 in Berlin.

Parkinson’s Disease is a progressive, degenerative disorder of the central nervous system. It is characterized by both motor (tremor, rigidity, bradykinesia, postural instability) and non-motor symptoms such as depression, sleep disorder, dementia, anxiety, cognitive issues and many more. After Alzheimer’s, Parkinson’s disease is the second most common neurodegenerative disease for which there is currently no known cure.

How It Works

MedEngine combines wireless connectivity and motion sensors with a traditional wristwatch to track and monitor Parkinson’s in patients. The styled, stainless steel watch tracks the motor systems of Parkinson’s throughout the day and relays this data to your smartphone. Complementing this data is the mobile app “Flytta,” which tracks non-motor symptoms of Parkinson’s and lifestyle factors like sleep, exercise, nutrition, medication, clinical assessments and more. Patients can view the combined analysis in an easy-to-understand format, allowing them to make better decisions about their choice of care. The data can also be easily shared with doctors and therapists. Flytta was co-financed by the European Regional Development Fund (ERDF).

The prevalence of Parkinson’s will double over the next 20 years. There is currently one specialist for every 500 patients in Europe. With Flytta, MedEngine is helping clinicians deliver a more tailored care pathway in less time.

On Twitter @medenginegmbh